GlassScriptPhysician profile
Amy L Dietrich
NPI 1053387522
$4,237.63
in general payments reported to CMS, 2019-2025
20 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $665 · 2023: $1,093 · 2024: $1,035 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,162 · Education: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,161.69 |
| Education | $411.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,385.97 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $681.95 | 2022-2025 | Ilumya |
| Lilly USA, LLC | $412.13 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $386.00 | 2022-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $240.21 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $183.19 | 2022-2025 | |
| Amgen INC. | $181.36 | 2023-2025 | Otezla, Otezla, Enbrel |
| Incyte Corporation | $110.74 | 2022-2023 | Opzelura |
| Sanofi-Aventis U.S. LLC | $96.99 | 2025 | |
| Leo Pharma INC. | $92.27 | 2025 | Adbry |
| Ucb, INC. | $81.98 | 2023-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $78.84 | 2022-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $76.63 | 2023-2024 | Arazlo, Jublia, Cabtreo |
| Novartis Pharmaceuticals Corporation | $71.80 | 2023-2024 | |
| Dermavant Sciences, INC. | $51.37 | 2023-2024 | Vtama |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.26 | 2024-2025 | |
| Organon LLC | $26.02 | 2024-2025 | Vtama |
| Galderma Laboratories, L.P. | $21.20 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $14.65 | 2025 | Zoryve |
| Botanix Sb INC | $14.07 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Dietrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.